Keeping Track: A Second Straight Burst Of FDA Approvals
Executive Summary
The latest drug approval and development news from our US FDA Performance Tracker.
You may also be interested in...
Individual Endpoints Pose Challenge For US FDA In Review Of Rare Disease Drug
FDA reviewer describes difficulties in reviewing application for Mepsevii for Sly syndrome; the experience provides perspective for other companies seeking to use novel endpoints.
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.